Amyotrophic Lateral Sclerosis Insights

Understanding amyotrophic lateral sclerosis: a guide for patients

January 30, 2025

Exclusive Report

Understanding amyotrophic lateral sclerosis: a guide for patients

Last week we introduced an essential guide created with AllMyHealth to help individuals and families better understand ALS. If you missed it, we're bringing it back this week to ensure you have access to this valuable resource.

Now available in audio format, you can read or listen at your convenience. Stay informed, empowered, and connected. Share with those who may benefit!

View the Full Report

The report is available for free online on the AllMyHealth website.

www.allmyhealth.io/report

Report Thumbnail

Top Stories

Machine Learning Uncovers ALS-Linked Genes

Researchers used machine learning to identify genes that may contribute to ALS, potentially leading to new therapeutic targets. This work could help understand how ALS progresses and how treatments might be developed.

Read More →

NP001 Shows 22-Month Survival Benefit in ALS Trials

Patients with amyotrophic lateral sclerosis who received NP001 lived significantly longer if their condition didn't progress during treatment, showing potential benefits for certain groups.

Read More →

FDA Approves Zydus' Usnoflast Phase IIb Trial for ALS

Zydus will conduct a new trial to see if Usnoflast slows ALS progression by measuring muscle function and lung capacity over several months.

Read More →

Former CFL LB Glenn Love Launches GoFundMe After ALS Diagnosis

Glenn Love, a former CFL linebacker, has started a GoFundMe campaign to support his family after being diagnosed with ALS at age 35. The campaign aims to help with the financial challenges associated with his condition.

Read More →

Latest Research

A recent study led by Bombaci et al. (2025) has identified peripherin (PRPH) as a promising early diagnostic and prognostic biomarker for amyotrophic lateral sclerosis (ALS). The study measured PRPH levels in plasma samples from individuals with ALS, other motor neuron diseases (MNDs), MND-mimic conditions, and healthy controls. Results showed that PRPH levels were significantly higher in ALS patients compared to MND-mimics and healthy controls, with strong correlations to disease progression and survival outcomes. A key finding was that higher PRPH levels were associated with a survival advantage, suggesting that PRPH could serve as both a diagnostic and prognostic marker.

These findings offer hope for earlier and more accurate ALS diagnosis, potentially distinguishing ALS from similar conditions at an earlier stage. Additionally, the correlation between PRPH levels and disease progression could help clinicians tailor treatment approaches based on biomarker readings. Further multicentre studies are needed to validate these results, but this research marks a step forward in improving diagnostic accuracy and patient management in ALS. If you or a loved one is affected by ALS, discussing emerging biomarker research with your healthcare provider may offer insights into future diagnostic and treatment developments.